top of page

SonALAsense presents preliminary data from clinical study in patients with deadly pediatric brain tumor

December 13, 2023

Tumor Regression and Improved Patient Performance are Among the Early Findings

FDA Grants Fast Track Designation to SonALAsense’s SONALA-001 in Combination with the INSIGHTEC Transcranial Ultrasound Device for Sonodynamic Therapy of DIPG, a Rare Pediatric Brain Cancer

November 14, 2023

Encouraging preliminary data from the ongoing DIPG clinical study to be presented at the 2023 Society for Neuro-Oncology Annual Meeting in Vancouver

Cancer Commons and SonALAsense: Putting Patients First

August 17, 2023

Learn more about Cancer Commons, an organization providing emotional support, clinical trial recommendations and other services for people who have been diagnosed with advanced cancer.

A Few Minutes with DIPG Nurse Navigator Leslie Jared

July 26, 2023

Looking for support with DIPG? Read the Q&A with the Director of Nurse Navigation at My DIPG Navigator to learn more about this patient-centered organization.

View Video: Our Director of Patient Advocacy moderated an insightful panel discussion at the White House Cancer Moonshot Brain Cancers Forum on GBM & DIPG on May 25, 2023

May 25, 2023

SonALAsense Welcomes Dr. Ely Benaim as Chief Medical Officer and Executive Vice President of Development

May 9, 2023

Highly accomplished Pediatric Oncologist from St. Jude Children’s Research Hospital and CMO for Novocure Brings Great Promise for People with Challenging Conditions

SonALAsense Announces Completion of First Cohort in Phase 2 Study of SONALA-001 Sonodynamic Therapy for Recurrent Glioblastoma

March 8, 2023

Company’s Phase 2 clinical trial aims to find meaningful clinical endpoints regarding tumor regression and survival rates.

Fast Company’s ‘World Changing Ideas Awards’ Honorably Mentions SonALAsense

January 11, 2023

Fast Company has listed SonALAsense as an honorable mention in the health category of their annual ‘World Changing Ideas Awards’.

SonALAsense Forges Ahead with First Patient Dosing for Devastating Childhood Brain Cancer

September 13, 2022

Multisite study will test sonodynamic therapy in pediatric patients with diffuse intrinsic pontine glioma (DIPG).

April Freeman Brings Her Personal and Professional Experience to SonALAsense as Patient Advocate

July 28, 2022

April recently joined SonALAsense as Director of Patient Advocacy and Engagement, helping build alliances with patient and trade organizations / associations to raise awareness of, and educate on, sonodynamic therapy and recruit patients for recurrent glioblastoma (GBM) and diffuse intrinsic pontine glioma (DIPG) clinical trials.

SonALAsense Achieves Significant Clinical, Growth and Funding Milestones Toward its Mission to Soundly Defeat Cancer

June 28, 2022

Company has received Safe to Proceed letters from FDA for two clinical trials in life-threatening brain tumors, DIPG trial is open and actively recruiting, it has expanded its executive leadership team and scientific advisory board and completed a Series B funding round.

SonALAsense Q&A with Dr. Scott Plotkin

June 21, 2022

Dr. Scott Plotkin, MD, PhD is the Executive Director at the Pappas Center for Neuro-Oncology at Massachusetts General Hospital and the Giovanni Armenise– Harvard Professor of Neurology at Harvard Medical School. He completed his neurology training at Mass General Brigham and Women's Hospital in Boston in 2002, and then trained in neuro-oncology at Mass General Hospital the following year. He has been on the faculty ever since and now also sits on the Scientific Advisory Board for SonALAsense.


bottom of page